Selinexor, anti-PD-1 antibody plus Golidocitinib for lymphoma, extranodal nk-t-cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Aug 2024: Trial registered, NCT06573138

The trials

NCT06573138: Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

State
Not started
Phase
Phase 2
People
18 planned
Started
1 Sep 2024
Primary completion
1 Jul 2027
Arms
Chemofree
Results
None posted
  1. 27 Aug 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.